Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ADH1C | P00326 | 2/20 | 0.33 |
| ▸ | ADH1A | P07327 | 2/20 | 0.33 |
| ▸ | ADH4 | P08319 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH7 | P40394 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4272165 | 0.98 | ALOX5 (0.41) | ALOX5ALDH1A1TSHRADH1CADH1A | |
| SCHEMBL7207291 | 0.81 | ALOX5 (0.37) | ALOX5ALDH1A1ADH1CADH1AADH4 | |
| SCHEMBL9430101 | 0.81 | ALOX5 (0.37) | ALOX5ALDH1A1TSHRADH1CADH1A | |
| SCHEMBL17580527 | 0.79 | ALOX5 (0.34) | ALOX5ADH1CADH1AADH4EPHX1 | |
| SCHEMBL3972433 | 0.76 | ALOX5 (0.44) | ALOX5ALDH1A1TSHREPHX1POLB | |
| SCHEMBL3971544 | 0.75 | ALOX5 (0.43) | ALOX5ALDH1A1TSHREPHX1POLB | |
| SCHEMBL3971572 | 0.73 | GBA1 (0.45) | ALOX5ALDH1A1TSHREPHX1SPHK1 | |
| SCHEMBL29105903 | 0.71 | ALOX5 (0.49) | ALOX5ALDH1A1POLBL3MBTL1TRPV1 | |
| SCHEMBL10881821 | 0.71 | ALOX5 (0.47) | ALOX5ALDH1A1TSHRADH1CADH1A | |
| SCHEMBL8922718 | 0.70 | NAAA (0.54) | ALOX5TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3800179-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2021-04-07 | — | — | EP | disclosed |
| EP-3656765-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2020-05-27 | — | — | EP | disclosed |
| EP-3653600-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2020-05-20 | — | — | EP | disclosed |
| EP-3650439-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2020-05-13 | — | — | EP | disclosed |
| EP-3636629-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2020-04-15 | — | — | EP | disclosed |
| EP-3287447-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-9133142-B2 | Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | GRUENENTHAL GMBH (DE) | 2015-09-15 | — | — | US | disclosed |
| EP-2595971-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2013-05-29 | — | — | EP | disclosed |
| US-20120022117-A1 | Salts or Co-Crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | GRUENENTHAL GMBH (DE) | 2012-01-26 | — | — | US | disclosed |
| WO-2012010316-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022117-A1 | Salts or Co-Crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | RCC2, EP300, SIGMAR1 | ALOX5 2616/4885ALDH1A1 3388/4885TSHR 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.